{"id":7648,"date":"2025-01-30T10:30:09","date_gmt":"2025-01-30T18:30:09","guid":{"rendered":"https:\/\/www.promisdx.com\/?p=7648"},"modified":"2025-10-30T14:58:59","modified_gmt":"2025-10-30T21:58:59","slug":"promis-dx-earlytect-bcd-delivers-high-accuracy-for-bladder-cancer-diagnosis","status":"publish","type":"post","link":"https:\/\/www.promisdx.com\/?p=7648","title":{"rendered":"Promis Dx EarlyTect BCD Delivers High Accuracy for Bladder Cancer Diagnosis"},"content":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces”][vc_column][vc_empty_space height=”” el_class=”header_news” css=”.vc_custom_1678221691977{background-image: url(https:\/\/www.promisdx.com\/wp-content\/uploads\/2022\/12\/newstemplateheader.png?id=6109) !important;}”][\/vc_column][\/vc_row][vc_section full_width=”stretch_row”][vc_row full_width=”stretch_row” layout=”boxed” css=”.vc_custom_1679355419891{margin-top: 1vw !important;}”][vc_column][vc_custom_heading text=”Promis Dx EarlyTect BCD Delivers High Accuracy for Bladder Cancer Diagnosis” font_container=”tag:h2|text_align:left|color:%230074b7|line_height:1″ google_fonts=”font_family:Montserrat%3Aregular%2C700|font_style:400%20regular%3A400%3Anormal” el_class=”min-txt-body-head”][vc_column_text el_class=”body-text”]<\/p>\n

Irvine, California, January<\/strong> 30, 2025<\/strong><\/p>\n

Promis Dx\u2019s <\/span>EarlyTect BCD<\/b>, a urinary DNA methylation test, demonstrated outstanding performance in detecting bladder cancer, especially high-grade and invasive cases. The test achieved a <\/span>sensitivity of 89.2%<\/b> for high-grade or invasive bladder cancer and <\/span>78.1%<\/b> for overall bladder cancer, ensuring reliable detection of aggressive tumors. Its <\/span>specificity reached 87.8%<\/b> for no high-grade or invasive cancer and <\/span>88.8%<\/b> for no bladder cancer, reducing false positives effectively. The test also showed a <\/span>positive predictive value (PPV) of 61.3%<\/b> for high-grade or invasive cancer and <\/span>63.3%<\/b> for overall bladder cancer, while maintaining an impressive <\/span>negative predictive value (NPV) of 97.6%<\/b>, minimizing the chances of missed diagnoses. With its high accuracy, EarlyTect BCD offers a <\/span>noninvasive, reliable diagnostic alternative<\/b>, potentially transforming early bladder cancer detection and improving patient outcomes. Promis Dx continues its mission to advance innovative diagnostic technologies that support early cancer detection and better clinical decision-making.<\/span><\/p>\n

Key EarlyTect BCD Results:<\/b><\/p>\n